ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) Meeting Abstract
| Authors: | Tripathy, D.; Tolaney, S. M.; Seidman, A. D.; Anders, C. K.; Ibrahim, N. K.; Rugo, H. S.; Twelves, C. J.; Dieras, V.; Müller, V.; Hannah, A. L.; Tagliaferri, M. A.; Cortes Castan, J. |
| Abstract Title: | ATTAIN: Phase III study of etirinotecan pegol (EP) vs treatment of physician's choice (TPC) in patients (pts) with metastatic breast cancer (MBC) who have stable brain metastases (BM) previously treated with an anthracycline, a taxane, and capecitabine (ATC) |
| Meeting Title: | 43rd ESMO Congress (ESMO 2018) |
| Journal Title: | Annals of Oncology |
| Volume: | 29 |
| Issue: | Suppl. 8 |
| Meeting Dates: | 2018 Oct 19-23 |
| Meeting Location: | Munich, Germany |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2018-10-01 |
| Start Page: | mdy272.350 |
| Language: | English |
| ACCESSION: | WOS:000459277300353 |
| PROVIDER: | wos |
| DOI: | 10.1093/annonc/mdy272.350 |
| Notes: | Meeting Abstract: 362TiP -- Appears on page viii118 of the abstract book -- Source: Wos |
